BR9914326A
(pt)
|
1998-10-08 |
2001-06-26 |
Astrazeneca Ab |
Uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou de redução da permeabilidade vascular em animais de sangue quente em necessidade de um tal tratamento
|
UA71945C2
(en)
*
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
ATE298237T1
(de)
|
1999-02-10 |
2005-07-15 |
Astrazeneca Ab |
Chinazolinderivate als angiogenesehemmer
|
ES2299434T3
(es)
*
|
1999-09-17 |
2008-06-01 |
ABBOTT GMBH & CO. KG |
Inhibidores de kinasa utilizados como agentes terapeuticos.
|
US7071199B1
(en)
|
1999-09-17 |
2006-07-04 |
Abbott Gmbh & Cco. Kg |
Kinase inhibitors as therapeutic agents
|
DK1292591T3
(da)
*
|
2000-06-22 |
2005-05-30 |
Pfizer Prod Inc |
Bicykliske derivater til behandling af abnorm cellevækst
|
NZ523358A
(en)
|
2000-08-09 |
2004-09-24 |
Astrazeneca Ab |
Quinoline derivatives having VEGF inhibiting activity
|
KR100589032B1
(ko)
|
2000-10-20 |
2006-06-14 |
에자이 가부시키가이샤 |
질소 함유 방향환 유도체
|
PT1370552E
(pt)
*
|
2001-03-23 |
2007-04-30 |
Bayer Pharmaceuticals Corp |
Inibidores de rho-quinase
|
ATE325795T1
(de)
*
|
2001-03-23 |
2006-06-15 |
Bayer Corp |
Rho-kinase inhibitoren
|
ATE330956T1
(de)
*
|
2001-04-13 |
2006-07-15 |
Pfizer Prod Inc |
Bizyklisch substituierte 4- aminopyridopyrimidinderivate
|
AU2002345792A1
(en)
|
2001-06-21 |
2003-01-08 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
CA2465068A1
(fr)
*
|
2001-11-03 |
2003-05-15 |
Astrazeneca Ab |
Derives quinazoline utilises en tant qu'agents antitumoraux
|
JP4220388B2
(ja)
*
|
2001-11-30 |
2009-02-04 |
ファイザー・プロダクツ・インク |
異常な細胞増殖を処置するための置換された二環式誘導体の製造方法
|
AU2002339687A1
(en)
*
|
2001-12-12 |
2003-06-23 |
Pfizer Products Inc. |
Quinazoline derivatives for the treatement of abnormal cell growth
|
JP2005516023A
(ja)
*
|
2001-12-19 |
2005-06-02 |
スミスクライン ビーチャム コーポレーション |
プロテインチロシンキナーゼ阻害剤としてのチエノピリミジン化合物
|
US20030143165A1
(en)
*
|
2002-01-25 |
2003-07-31 |
Allan Evans |
NSAID-containing topical formulations that demonstrate chemopreventive activity
|
WO2003064413A1
(fr)
|
2002-02-01 |
2003-08-07 |
Astrazeneca Ab |
Composes de quinazoline
|
TW200302722A
(en)
*
|
2002-02-13 |
2003-08-16 |
Astrazeneca Ab |
Therapeutic agents
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
WO2003094830A2
(fr)
*
|
2002-05-07 |
2003-11-20 |
Neurosearch A/S |
Nouveaux derives d'ethynyl azacycliques
|
US8313760B2
(en)
*
|
2002-05-24 |
2012-11-20 |
Angiotech International Ag |
Compositions and methods for coating medical implants
|
ES2330326T3
(es)
*
|
2002-05-24 |
2009-12-09 |
Angiotech International Ag |
Composiciones y metodos para recubrir implantes medicos.
|
WO2004013141A1
(fr)
|
2002-08-06 |
2004-02-12 |
Astrazeneca Ab |
Pyridines condensees et pyrimidines a activite tie2 (tek)
|
JP4611745B2
(ja)
|
2002-11-20 |
2011-01-12 |
アレイ バイオファーマ、インコーポレイテッド |
ErbB2及びEGFR阻害剤としてのシアノグアニジン及びシアノアミジン
|
US20040186160A1
(en)
*
|
2002-12-13 |
2004-09-23 |
Sugen, Inc. |
Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
|
PL377686A1
(pl)
*
|
2002-12-18 |
2006-02-06 |
Pfizer Products Inc. |
Pochodne 4-anilinochinazoliny do leczenia anormalnego wzrostu komórek
|
JP3814285B2
(ja)
*
|
2002-12-19 |
2006-08-23 |
ファイザー・インク |
眼疾患の治療に有用なプロテインキナーゼ阻害剤としての2−(1h−インダゾール−6−イルアミノ)−ベンズアミド化合物
|
GB0309009D0
(en)
*
|
2003-04-22 |
2003-05-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
WO2004106308A1
(fr)
*
|
2003-05-27 |
2004-12-09 |
Pfizer Products Inc. |
Quinazolines et pyrido[3,4-d] pyrimidines utilises comme inhibiteurs de recepteurs tyrosine kinase
|
WO2006074147A2
(fr)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics, Inc. |
Composes et utilisation therapeutique associee
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
US7618975B2
(en)
*
|
2003-07-03 |
2009-11-17 |
Myriad Pharmaceuticals, Inc. |
4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
HN2004000285A
(es)
*
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
CN1882573A
(zh)
*
|
2003-09-16 |
2006-12-20 |
阿斯利康(瑞典)有限公司 |
作为酪氨酸激酶抑制剂的喹唑啉衍生物
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
EP1683785B1
(fr)
|
2003-11-11 |
2013-10-16 |
Eisai R&D Management Co., Ltd. |
Derive d'uree et son procede de production
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
CA2536242A1
(fr)
*
|
2003-11-20 |
2005-06-09 |
Angiotech International Ag |
Capteurs implantables et pompes implantables et agents anti-cicatrisation
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
DE602005010824D1
(de)
|
2004-02-03 |
2008-12-18 |
Astrazeneca Ab |
Chinazolinderivate
|
WO2005094830A1
(fr)
*
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinaisons d'inhibiteurs de transduction de signaux
|
JPWO2005095419A1
(ja)
*
|
2004-04-01 |
2008-02-21 |
武田薬品工業株式会社 |
チアゾロピリミジン誘導体
|
MEP8409A
(en)
*
|
2004-06-02 |
2011-12-20 |
|
Fused heterocyclic compound
|
WO2005118572A1
(fr)
*
|
2004-06-04 |
2005-12-15 |
Astrazeneca Ab |
Derives de quinazoline utilises comme tyrosine kinases du recepteur erbb
|
SG156650A1
(en)
*
|
2004-07-16 |
2009-11-26 |
Sunesis Pharmaceuticals Inc |
Thienopyrimidines useful as aurora kinase inhibitors
|
MX2007001399A
(es)
*
|
2004-08-02 |
2007-04-18 |
Osi Pharm Inc |
Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas.
|
UA87153C2
(ru)
|
2004-08-26 |
2009-06-25 |
Пфайзер Инк. |
Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
|
CA2577937C
(fr)
*
|
2004-08-26 |
2010-12-21 |
Pfizer Inc. |
Composes aminoheteroaryle a substitution pyrazole servant d'inhibiteurs de proteine kinase
|
WO2006021886A1
(fr)
*
|
2004-08-26 |
2006-03-02 |
Pfizer Inc. |
Composes aminoheteroaryles en tant qu'inhibiteurs des proteines tyrosine kinases
|
KR20070053205A
(ko)
|
2004-09-17 |
2007-05-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
의약 조성물
|
US7285569B2
(en)
|
2004-09-24 |
2007-10-23 |
Hoff Hoffmann-La Roche Inc. |
Tricycles, their manufacture and use as pharmaceutical agents
|
TW200624431A
(en)
|
2004-09-24 |
2006-07-16 |
Hoffmann La Roche |
Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
|
US20060107555A1
(en)
*
|
2004-11-09 |
2006-05-25 |
Curtis Marc D |
Universal snow plow adapter
|
JP4881875B2
(ja)
|
2004-12-14 |
2012-02-22 |
アストラゼネカ アクチボラグ |
抗腫瘍剤としてのピラゾロピリミジン化合物
|
JP2008526776A
(ja)
*
|
2005-01-03 |
2008-07-24 |
ミリアド ジェネティクス, インコーポレイテッド |
脳癌の治療の方法
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
GB0504474D0
(en)
*
|
2005-03-04 |
2005-04-13 |
Astrazeneca Ab |
Chemical compounds
|
EP1863848A4
(fr)
|
2005-03-31 |
2009-09-23 |
Agensys Inc |
Anticorps et molecules correspondantes qui se fixent aux proteines 161p2f10b
|
MX2007012477A
(es)
|
2005-04-14 |
2007-11-08 |
Hoffmann La Roche |
Derivados de aminopirazol, su fabricacion y uso como agentes farmaceuticos.
|
GEP20115226B
(en)
|
2005-04-26 |
2011-06-10 |
Pfizer |
P-cadherin antibodies
|
GB0508715D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
GB0508717D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
ES2371774T3
(es)
|
2005-06-03 |
2012-01-10 |
Abbott Laboratories |
Derivados de ciclobutilamina.
|
EP1925676A4
(fr)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
Procédé d'analyse de l' effet d 'un inhibiteur de vascularisation
|
NZ566774A
(en)
*
|
2005-09-07 |
2011-11-25 |
Pfizer |
Human monoclonal antibodies to activin receptor-like kinase-1
|
EP2372363A1
(fr)
|
2005-09-20 |
2011-10-05 |
OSI Pharmaceuticals, Inc. |
Marqueurs biologiques prédictifs d'une réaction anticancéreuse aux inhibiteurs kinase du récepteur du facteur de croissance 1 analogue à l'insuline
|
EP1940825A1
(fr)
*
|
2005-09-20 |
2008-07-09 |
Astra Zeneca AB |
Derives de quinazoline utilises comme agents anticancereux
|
JP2009508918A
(ja)
*
|
2005-09-20 |
2009-03-05 |
アストラゼネカ アクチボラグ |
癌治療のためのerbB受容体チロシンキナーゼ阻害剤としての4−(1H−インダゾール−5−イル]アミノ)キナゾリン化合物
|
US7576110B2
(en)
|
2005-09-22 |
2009-08-18 |
Abbott Laboratories |
Benzothiazole cyclobutyl amine derivatives
|
EP1957499A1
(fr)
*
|
2005-12-02 |
2008-08-20 |
AstraZeneca AB |
Dérivés de la quinazoline à substitution 4-anilino comme inhibiteurs de la tyrosine kinase
|
WO2007063293A1
(fr)
*
|
2005-12-02 |
2007-06-07 |
Astrazeneca Ab |
Derives de quinazoline utilises en tant qu’inhibiteurs des tyrosine kinases erbb associees au recepteur
|
TW200730527A
(en)
*
|
2005-12-02 |
2007-08-16 |
Takeda Pharmaceuticals Co |
Fused heterocyclic compound
|
EP1963320A1
(fr)
*
|
2005-12-07 |
2008-09-03 |
OSI Pharmaceuticals, Inc. |
Composes inhibant les pyrrolopyridine kinases
|
US7572809B2
(en)
|
2005-12-19 |
2009-08-11 |
Hoffmann-La Roche Inc. |
Isoquinoline aminopyrazole derivatives
|
ES2378473T3
(es)
|
2005-12-21 |
2012-04-12 |
Abbott Laboratories |
Compuestos antivirales
|
JP2009521480A
(ja)
|
2005-12-21 |
2009-06-04 |
アボット・ラボラトリーズ |
抗ウイルス化合物
|
US7915411B2
(en)
|
2005-12-21 |
2011-03-29 |
Abbott Laboratories |
Anti-viral compounds
|
US20070231298A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Cell Genesys, Inc. |
Cytokine-expressing cancer immunotherapy combinations
|
KR20090007792A
(ko)
|
2006-05-09 |
2009-01-20 |
화이자 프로덕츠 인크. |
시클로알킬아미노산 유도체 및 이들의 제약 조성물
|
CA2652442C
(fr)
|
2006-05-18 |
2014-12-09 |
Eisai R & D Management Co., Ltd. |
Agent antitumoral destine au cancer de la thyroide
|
US9108948B2
(en)
|
2006-06-23 |
2015-08-18 |
Abbvie Inc. |
Cyclopropyl amine derivatives
|
NZ611323A
(en)
|
2006-06-23 |
2014-10-31 |
Abbvie Bahamas Ltd |
Cyclopropyl amine derivatives as histamin h3 receptor modulators
|
US8865737B2
(en)
|
2006-08-28 |
2014-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
EP1921070A1
(fr)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
heterocycles bicycliques, medicaments á base de ces composes, leur usage et procédé pour leur preparation
|
WO2008072634A1
(fr)
|
2006-12-12 |
2008-06-19 |
Takeda Pharmaceutical Company Limited |
Composé hétérocyclique condensé
|
EP2094276A4
(fr)
|
2006-12-20 |
2011-01-05 |
Abbott Lab |
Composés antiviraux
|
CA2676796C
(fr)
|
2007-01-29 |
2016-02-23 |
Eisai R & D Management Co., Ltd. |
Composition destinee au traitement d'un cancer de l'estomac de type indifferencie
|
KR100799821B1
(ko)
*
|
2007-02-05 |
2008-01-31 |
동화약품공업주식회사 |
신규한 이마티닙 캠실레이트 및 그의 제조방법
|
KR20090116782A
(ko)
|
2007-02-06 |
2009-11-11 |
베링거 인겔하임 인터내셔날 게엠베하 |
바이사이클릭 헤테로사이클, 당해 화합물을 함유하는 약물, 이의 용도 및 이의 제조방법
|
JP5926487B2
(ja)
|
2007-04-13 |
2016-05-25 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
ErbB療法に耐性である癌を治療するための方法
|
WO2008127707A1
(fr)
*
|
2007-04-13 |
2008-10-23 |
Dana Farber Cancer Institute, Inc. |
Établissement du profil de récepteurs tyrosine kinases
|
WO2009000489A1
(fr)
|
2007-06-25 |
2008-12-31 |
F. Hoffmann-La Roche Ag |
Dérivés amido du benzimidazole en tant qu'inhibiteurs de kinase
|
WO2009033094A2
(fr)
|
2007-09-07 |
2009-03-12 |
Agensys, Inc. |
Anticorps et molécules apparentées qui se lient aux protéines 24p4c12
|
CA2704000C
(fr)
|
2007-11-09 |
2016-12-13 |
Eisai R&D Management Co., Ltd. |
Combinaison d'une substance antiangiogenique et d'un complexe de platine antitumoral
|
DK2245026T3
(da)
|
2008-02-07 |
2012-10-15 |
Boehringer Ingelheim Int |
Spirocycliske heterocycler, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåde til deres fremstilling
|
US7932036B1
(en)
|
2008-03-12 |
2011-04-26 |
Veridex, Llc |
Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
|
EP2253633A4
(fr)
|
2008-03-12 |
2012-02-29 |
Takeda Pharmaceutical |
Composé hétérocyclique fusionné
|
ES2444128T3
(es)
|
2008-05-13 |
2014-02-24 |
Astrazeneca Ab |
Nueva SAL-554
|
JP2011525915A
(ja)
*
|
2008-06-26 |
2011-09-29 |
アムジエン・インコーポレーテツド |
キナーゼ阻害薬としてのアルキニルアルコール類
|
US20100029675A1
(en)
*
|
2008-07-25 |
2010-02-04 |
Hwang Soo-In |
Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use
|
CA2733153C
(fr)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Heterocycles a substitution cyclohexyloxy, medicaments contenant ces composes, leur utilisation et procedes pour les preparer
|
TW201014860A
(en)
|
2008-09-08 |
2010-04-16 |
Boehringer Ingelheim Int |
New chemical compounds
|
EP2241565A1
(fr)
|
2009-01-15 |
2010-10-20 |
Universität Leipzig |
Composés inhibiteurs de l'aurora kinase
|
WO2010090764A1
(fr)
|
2009-02-09 |
2010-08-12 |
Supergen, Inc. |
Inhibiteurs pyrrolopyrimidinyle de l'axi kinase
|
WO2010099139A2
(fr)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Thérapie anti-cancer combinée
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US20100222381A1
(en)
|
2009-02-27 |
2010-09-02 |
Hariprasad Vankayalapati |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
WO2010099138A2
(fr)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US9186353B2
(en)
|
2009-04-27 |
2015-11-17 |
Abbvie Inc. |
Treatment of osteoarthritis pain
|
CA2772194A1
(fr)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Derives de benzimidazole
|
US20110217309A1
(en)
|
2010-03-03 |
2011-09-08 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011109572A2
(fr)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
|
CA2802644C
(fr)
|
2010-06-25 |
2017-02-21 |
Eisai R & D Management Co., Ltd. |
Agent anticancereux utilisant des composes ayant un effet inhibiteur de kinase en combinaison
|
WO2012016021A2
(fr)
|
2010-07-28 |
2012-02-02 |
Veridex, Llc |
Procédés de détermination de réponse de la leucémie myéloïde aiguë à traitement par inhibiteurs de la farnésyltransférase
|
US8853390B2
(en)
|
2010-09-16 |
2014-10-07 |
Abbvie Inc. |
Processes for preparing 1,2-substituted cyclopropyl derivatives
|
WO2012052948A1
(fr)
|
2010-10-20 |
2012-04-26 |
Pfizer Inc. |
Dérivés de pyridine-2 en tant que modulateurs des récepteurs smoothened
|
KR20140016245A
(ko)
*
|
2010-11-09 |
2014-02-07 |
후지안 하이시 파머수티클스, 인코포레이티드 |
키나아제 활성을 증진시키기 위한 화합물 및 이의 응용
|
WO2012116040A1
(fr)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de la kinase du récepteur du facteur de croissance 1 analogue à l'insuline dans le carcinome hépatocellulaire
|
BR112013021941B1
(pt)
|
2011-04-18 |
2022-11-16 |
Eisai R & D Management Co., Ltd |
Agente terapêutico para tumor
|
CA2830972C
(fr)
|
2011-04-19 |
2018-11-20 |
Pfizer Inc. |
Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicite a mediation cellulaire dependante d'un anticorps (adcc) pour le traitement du cancer
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
WO2013013188A1
(fr)
|
2011-07-21 |
2013-01-24 |
Tolero Pharmaceuticals, Inc. |
Inhibiteurs de protéine kinase hétérocycliques
|
CN103814030A
(zh)
|
2011-09-22 |
2014-05-21 |
辉瑞大药厂 |
吡咯并嘧啶及嘌呤衍生物
|
WO2013068902A1
(fr)
|
2011-11-08 |
2013-05-16 |
Pfizer Inc. |
Procédés de traitement de troubles inflammatoires utilisant des anticorps anti-m-csf
|
TWI577671B
(zh)
*
|
2011-11-14 |
2017-04-11 |
Sunshine Lake Pharma Co Ltd |
Aminoquinazoline derivatives and salts thereof and methods of use thereof
|
WO2013152252A1
(fr)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Polythérapie antinéoplasique
|
WO2014062838A2
(fr)
|
2012-10-16 |
2014-04-24 |
Tolero Pharmaceuticals, Inc. |
Modulateurs de pkm2 et procédés pour les utiliser
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
AU2013364953A1
(en)
|
2012-12-21 |
2015-04-30 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
US9468681B2
(en)
|
2013-03-01 |
2016-10-18 |
California Institute Of Technology |
Targeted nanoparticles
|
RU2693480C2
(ru)
|
2013-03-14 |
2019-07-03 |
Толеро Фармасьютикалз, Инк. |
Ингибиторы jak2 и alk2 и способы их использования
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
NZ714049A
(en)
|
2013-05-14 |
2020-05-29 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
CN103784412A
(zh)
*
|
2014-01-15 |
2014-05-14 |
青岛市肿瘤医院 |
一种盐酸埃克替尼分散片及其制备方法
|
WO2015155624A1
(fr)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dérivés de dihydropyrrolopyrimidine
|
HUE046518T2
(hu)
|
2014-04-30 |
2020-03-30 |
Pfizer |
Cikloalkilcsoporthoz kapcsolt diheterociklusos származékok
|
WO2016001789A1
(fr)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer
|
KR102329681B1
(ko)
|
2014-08-28 |
2021-11-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
고순도의 퀴놀린 유도체 및 이를 제조하는 방법
|
PT3263106T
(pt)
|
2015-02-25 |
2024-01-12 |
Eisai R&D Man Co Ltd |
Método para suprimir o amargor do derivado de quinolina
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
MX2017013383A
(es)
|
2015-04-20 |
2017-12-07 |
Tolero Pharmaceuticals Inc |
Prediccion de respuesta a alvocidib mediante perfilado mitocondrial.
|
BR112017024933A8
(pt)
|
2015-05-18 |
2022-10-18 |
Tolero Pharmaceuticals Inc |
Alvocidib produce com a bioavailabilidade aumentada
|
AU2016279474B2
(en)
|
2015-06-16 |
2021-09-09 |
Eisai R&D Management Co., Ltd. |
Anticancer agent
|
US10287401B2
(en)
|
2015-07-01 |
2019-05-14 |
California Institute Of Technology |
Cationic mucic acid polymer-based delivery systems
|
WO2017009751A1
(fr)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Dérivés de pyrimidine
|
WO2017024073A1
(fr)
|
2015-08-03 |
2017-02-09 |
Tolero Pharmaceuticals, Inc. |
Thérapies combinatoires pour le traitement du cancer
|
US20180371551A1
(en)
|
2015-12-03 |
2018-12-27 |
Agios Pharmaceuticals, Inc. |
Mat2a inhibitors for treating mtap null cancer
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
AU2017379847B2
(en)
|
2016-12-19 |
2022-05-26 |
Sumitomo Pharma Oncology, Inc. |
Profiling peptides and methods for sensitivity profiling
|
WO2019055579A1
(fr)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
Régime de traitement pour des cancers qui sont insensibles aux inhibiteurs de bcl-2 à l'aide de l'inhibiteur de mcl-1 alvocidib
|
US11512067B2
(en)
|
2017-09-14 |
2022-11-29 |
Daiichi Sankyo Company, Limited |
Compound having cyclic structure
|
WO2019075367A1
(fr)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
Activateurs de pkm2 en combinaison avec des espèces réactives de l'oxygène pour le traitement du cancer
|
JOP20180094A1
(ar)
|
2017-10-18 |
2019-04-18 |
Hk Inno N Corp |
مركب حلقي غير متجانس كمثبط بروتين كيناز
|
CA3085593A1
(fr)
*
|
2017-12-18 |
2019-06-27 |
Sterngreene, Inc. |
Composes de pyrimidine utiles en tant qu'inhibiteurs de tyrosine kinase
|
JP7483193B2
(ja)
|
2018-06-13 |
2024-05-15 |
カリフォルニア・インスティテュート・オブ・テクノロジー |
血脳バリアを越えるためのナノ粒子とそれを用いた治療法
|
US11040038B2
(en)
|
2018-07-26 |
2021-06-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
|
WO2020068867A1
(fr)
|
2018-09-25 |
2020-04-02 |
Black Diamond Therapeutics, Inc. |
Dérivés de quinazoline utilisés en tant qu'inhibiteur de tyrosine kinase, compositions, leurs procédés de préparation et leur utilisation
|
US11034710B2
(en)
|
2018-12-04 |
2021-06-15 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
CA3127502A1
(fr)
|
2019-02-12 |
2020-08-20 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Formulations comprenant des inhibiteurs de proteine kinase heterocycliques
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
EP3941463A1
(fr)
|
2019-03-22 |
2022-01-26 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprenant des modulateurs de pkm2 et méthodes de traitement les utilisant
|
WO2021155006A1
(fr)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations
|
WO2021179274A1
(fr)
*
|
2020-03-13 |
2021-09-16 |
Suzhou Zanrong Pharma Ltd. |
Inhibiteurs de récepteurs erbb utilisés comme agents antitumoraux
|
KR102234530B1
(ko)
*
|
2020-09-01 |
2021-03-31 |
대한민국 |
신규 톨트라주릴 유도체 및 이를 포함하는 쿠도아충 예방·치료를 위한 약학 조성물
|